Yeni Bir β-laktam/β-laktamaz İnhibitörü: Seftolozan/tazobaktam

Kıvanç ŞEREFHANOĞLU

doi:10.4274/mjima.galenos.2019.2019.10

Yeni Bir β-laktam/β-laktamaz İnhibitörü: Seftolozan/tazobaktam

PDF

DERLEME

Yeni Bir β-laktam/β-laktamaz İnhibitörü: Seftolozan/tazobaktam

Mediterr J Infect Microb Antimicrob 2019;8:10-10 DOI: 10.4274/mjima.galenos.2019.2019.10

PDF

İzin

Öz

Seftolozan/tazobaktam yeni kuşak sefalosporin ve β-laktamaz inhibitörü kombinasyonu olan bir antibiyotiktir. On sekiz yaş ve üzerindeki erişkinlerde meydana gelen komplike üriner sistem enfeksiyonları ve metronidazol ile kombine edilerek komplike intraabdominal enfeksiyonların tedavisinde Amerikan Gıda ve İlaç Dairesi onayı almıştır. Başlıca etki spektrumu çoklu ilaç dirençli (ÇİD) Pseudomonas aeruginosa ve diğer aerobik Gram-olumsuz bakterilerdir (GNB). Başlıca karakteristik özellikleri: (1) P. aeruginosa’nın penisilin bağlayan proteinlerine yüksek afinitesi olması, (2) dış membran penetrasyonunun yüksek olması ve bu nedenle efluks pompası aktivitesinden daha az etkilenmesi, (3) AmpC β-laktamaz, primitif b-laktamazlar (TEM-1, TEM-2, SHV-1 ve OXA-1) ve genişlemiş spektrumlu β-laktamaz olumlu bakterilere etkili olmasıdır. Buna karşın, metallo-β-laktamaz ve Klebsiella pneumoniae karbapenemazları enzimleri üreten patojenlere etkisizdir. Seftolozan/tazobaktamın özellikle tedavi seçeneğinin kısıtlı olduğu ÇİD GNB’nin neden olduğu enfeksiyonların tedavisinde faydalı olacağı düşünülmektedir. Bu yazıda, henüz ülkemizde kullanıma girmemiş olan bu antibiyotiğin farmakokinetik özellikleri, antimikrobiyal spektrumu ve güncel çalışmalardaki verileri derlenmiştir.

Anahtar Kelimeler: CRE, GSBL, hemodiyaliz, kronik böbrek yetmezliği, komplike intra-abdominal enfeksiyonlar

Kaynakça

1

Munoz-Price LS, Poirel L, Bonomo RA, Schwaber MJ, Daikos GL, Cormican M, Cornaglia G, Garau J, Gniadkowski M, Hayden MK, Kumarasamy K, Livermore DM, Maya JJ, Nordmann P, Patel JB, Paterson DL, Pitout J, Villegas MV, Wang H, Woodford N, Quinn JP. Clinical epidemiology of the global expansion of Klebsiella pneumoniae carbapenemases. Lancet Infect Dis. 2013;13:785-96.

2

Sader HS, Farrell DJ, Flamm RK, Jones RN. Antimicrobial susceptibility of Gram negative organisms isolated from patients hospitalised with pneumonia in US and European hospitals: results from the SENTRY Antimicrobial Surveillance Program, 2009-2012. Int J Antimicrob Agents. 2014;43:328-34.

3

van Duin D, Kaye KS, Neuner EA, Bonomo RA. Carbapenem-resistant Enterobacteriaceae: a review of treatment and outcomes. Diagn Microbiol Infect Dis. 2013;75:115-20.

4

van Duin D, Bonomo RA. Ceftazidime/avibactam and ceftolozane/ tazobactam: Second-generation β-lactam/ β-lactamase inhibitor combinations. Clin Infect Dis. 2016;63:234-41.

5

Hong MC, Hsu DI, Bounthavong M. Ceftolozane/tazobactam: a novel antipseudomonal cephalosporin and β-lactamase-inhibitor combination. Infect Drug Resist. 2013;6:215-23.

6

Moya B, Zamorano L, Juan C, Ge Y, Oliver A. Affinity of the new cephalosporin CXA-101 to penicillin-binding proteins of Pseudomonas aeruginosa. Antimicrob Agents Chemother. 2010;54:3933-7.

7

Cluck D, Lewis P, Stayer B, Spivey J, Moorman J. Ceftolozane-tazobactam: a new-generation cephalosporin. Am J Health Syst Pharm. 2015;72:2135-46.

8

Miller B, Hershberger E, Benziger D, Trinh M, Friedland I. Pharmacokinetics and safety of intravenous ceftolozane-tazobactam in healthy adult subjects following single and multiple ascending doses. Antimicrob Agents Chemother. 2012;56:3086-91.

9

Chandorkar G, Xiao A, Mouksassi MS, Hershberger E, Krishna G. Population pharmacokinetics of ceftolozane/tazobactam in healthy volunteers, subjects with varying degrees of renal function and patients with bacterial infections. J Clin Pharmacol. 2015;55:230-9.

10

Cada DJ, Wageman J, Baker DE, Levien TL. Ceftolozane/Tazobactam. Hosp Pharm. 2015;50:526-33.

11

Farrell DJ, Sader HS, Flamm RK, Jones RN. Ceftolozane/tazobactam activity tested against Gram-negative bacterial isolates from hospitalised patients with pneumonia in US and Europeanmedical centres (2012). Int J Antimicrob Agents. 2014;43:533-9.

12

Sader HS, Castanheira M, Flamm RK, Farrell DJ, Jones RN. Antimicrobial activity of ceftazidime-avibactam against Gram-negative organisms collected from U.S. medical centers in 2012. Antimicrob Agents Chemother. 2014;58:1684-92.

13

Snydman DR, McDermott LA, Jacobus NV. Activity of ceftolozanetazobactam against a broad spectrum of recent clinical anaerobic isolates. Antimicrob Agents Chemother. 2014;58:1218-23.

14

Dubreuil LJ, Mahieux S, Neut C, Miossec C, Pace J. Anti-anaerobic activity of a new beta-lactamase inhibitor NXL104 in combination with beta-lactams and metronidazole. Int J Antimicrob Agents. 2012;39:500-4.

15

Lexington, MA. Zerbaxa (ceftolozane/tazobactam) [prescribing information]. Cubist Pharmaceuticals. 2014.

16

Livermore DM, Mushtaq S, Meunier D, Hopkins KL, Hill R, Adkin R, Chaudhry A, Pike R, Staves P, Woodford N; BSAC Resistance Surveillance Standing Committee. Activity of ceftolozane/tazobactam against surveillance and ‘problem’ Enterobacteriaceae, Pseudomonas aeruginosa and nonfermenters from the British Isles. J Antimicrob Chemother. 2017;72:2278- 89.

17

Pfaller MA, Shortridge D, Sader HS, Castanheira M, Flamm RK. Ceftolozane/ tazobactam activity against drug-resistant Enterobacteriaceae and Pseudomonas aeruginosa causing healthcare associated infections in the Asia-Pacific region (minus China, Australia and New Zealand): report from an Antimicrobial Surveillance Programme (2013-2015). Int J Antimicrob Agents. 2018;51:181-9.

18

Farrell DJ, Flamm RK, Sader HS, Jones RN. Antimicrobial activity of ceftolozane-tazobactam tested against Enterobacteriaceae and Pseudomonas aeruginosa with various resistance patterns isolated in U.S. Hospitals (2011-2012). J Antimicrob Agents Chemother. 2013;57:6305-10.

19

Walkty A, Adam H, Baxter M, Lagacé-Wiens P, Karlowsky JA, Hoban DJ, Zhanel GG. In vitro activity of ceftolozane/tazobactam versus antimicrobial non-susceptible Pseudomonas aeruginosa clinical isolates including MDR and XDR isolates obtained from across Canada as part of the CANWARD study, 2008-16. J Antimicrob Chemother. 2018;73:703-8.

20

Skoglung E, Ledesma KR, Lasco TM, Tam VH. Ceftolozane/tazobactam activity against meropenem-non-susceptible Pseudomonas aeruginosa bloodstream infection isolates. J Glob Antimicrob Resist. 2017;11:154-5.

21

Giani T, Arana F, Pollini S, Di Pilato V, D’Andrea MM, Henrici De Angelis L, Bassetti M, Rossolini GM; Pseudomonas aeruginosa Working Group. Italian nationwide survey on Pseudomonas aeruginosa from invasive infections: activity of ceftolozane/tazobactam and comparators, and molecular epidemiology of carbapenemase producers. J Antimicrob Chemother. 2018;73:664-71.

22

Seifert H, Irrgang BK, Kresken M; German Ceftolozane/Tazobactam Study Group. In vitro activity of ceftolozane/tazobactam against Pseudomonas aeruginosa and Enterobacteriaceae isolates recovered from hospitalized patients in Germany. Int J Antimicrob Agents. 2018;51:227-34.

23

Gentile I, Maraolo AE, Borgia G. What is the role of the new β-lactam/β- lactamase inhibitors ceftolozane/tazobactam and ceftazidime/avibactam? Expert Rev Anti-Infect Ther. 2016;14:875-8.

24

Dinh A, Wyplosz B, Kernéis S, Lebeaux D, Bouchand F, Duran C, Béraud G, Lazaro P, Davido B, Hénard S, Canouï E, Ferry T, Wolff M. Use of ceftolozane/ tazobactam as salvage therapy for infections due to extensively drugresistant Pseudomonas aeruginosa. Int J Antimicrob Agents. 2017;49:782- 3.

25

Castón JJ, De la Torre A, Ruiz-Camps I, Sorlí ML, Torres V, Torre-Cisnerosa J. Salvage Therapy with CeftolozaneTazobactam for Multidrug-Resistant Pseudomonas aeruginosa Infections. J Antimicrob Chemother. 2017:61.

26

Munita JM, Aitken SL, Miller WR, Perez F, Rosa R, Shimose LA, Lichtenberger PN, Abbo LM, Jain R, Nigo M, Wanger A, Araos R, Tran TT, Adachi J, Rakita R, Shelburne S, Bonomo RA, Arias CA. Multicenter Evaluation of Ceftolozane/ Tazobactam for Serious Infections Caused by Carbapenem-Resistant Pseudomonas aeruginosa. Clin Infect Dis. 2017:65:158-61.

27

Dietl B, Sánchez I, Arcenillas P, Cuchi E, Gómez L, González de Molina FJ, Boix-Palop L, Nicolás J, Calbo E. Ceftolozane/tazobactam in the treatment of osteomyelitis and skin and soft-tissue infections due to extensively drugresistant Pseudomonas aeruginosa: clinical and microbiological outcomes. Int J Antimicrob Agents. 2018;51:498-502.

28

Gelfand MS, Cleveland KO. Ceftolozane/Tazobactam Therapy of Respiratory Infections due to Multidrug-Resistant Pseudomonas aeruginosa. Clin Infect Dis. 2015;61:853-5.

29

Popejoy MW, Paterson DL, Cloutier D, Huntington JA, Miller B, Bliss CA, Steenbergen JN, Hershberger E, Umeh O, Kaye KS. Efficacy of ceftolozane/ tazobactam against urinary tract and intra-abdominal infections caused by ESBL-producing Escherichia coli and Klebsiella pneumoniae: a pooled analysis of Phase 3 clinical trials. J Antimicrob Chemother. 2017;72:268-72.

30

Lucasti C, Hershberger E, Miller B, Yankelev S, Steenbergen J, Friedland I, Solomkin J. Multicenter, double-blind, randomized, phase II trial to assess the safety and efficacy of ceftolozane-tazobactam plus metronidazole compared with meropenem in adult patients with complicated intraabdominal infections. Antimicrob Agents Chemother. 2014;58:5350-7.

31

Solomkin J, Hershberger E, Miller B, Popejoy M, Friedland I, Steenbergen J, Yoon M, Collins S, Yuan G, Barie PS, Eckmann C. Ceftolozane/tazobactam plus metronidazole for complicated intra-abdominal infections in an era of multidrug resistance: results from a randomized, double-blind, phase 3 trial (ASPECT-cIAI). Clin Infect Dis. 2015;60:1462-71.